Impella registries show better survival than CHIP-BCIS3, but can Johnson & Johnson explain the conflicting evidence?
Johnson & Johnson has highlighted three observational analyses involving 1,379 Impella-supported high-risk PCI patients, reporting mortality rates below selected figures from CHIP-BCIS3. However, the original randomised study found no significant clinical advantage from routine pump use, leaving patient selection and treatment strategy important unresolved questions.